MedPath

Smurfit WestRock

🇬🇧United Kingdom
Ownership
-
Employees
47K
Market Cap
-
Website
Introduction

Smurfit WestRock Plc engages in the development and provision of packaging solutions. Its products include corrugated packaging, corrugated sheet boards, hexacomb packaging, and solid boards. The company was founded on July 6, 2017 and is headquartered in Dublin, Ireland.

Eli Lilly's Zepbound Demonstrates Superior Weight Loss Compared to Novo Nordisk's Wegovy in Head-to-Head Trial

• Eli Lilly's Zepbound (tirzepatide) led to a 20.2% average weight loss, significantly outperforming Wegovy (semaglutide) at 13.7% in a 72-week clinical trial. • The SURMOUNT-5 trial included overweight or obese adults without diabetes, showing Zepbound users experienced 47% more relative weight loss than Wegovy users. • Zepbound, a dual GIP and GLP-1 receptor agonist, helped 31.6% of participants achieve at least 25% body weight loss, compared to 16.1% with Wegovy. • The study's findings may influence treatment choices, with Zepbound potentially becoming a preferred option for greater weight loss outcomes, pending further data on tolerability.
© Copyright 2025. All Rights Reserved by MedPath